Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori

Published:2021-01-15 Issue:1 Volume:15 Page:53-60
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Lee Jung Won¹²^ORCID,Kim Nayoung¹³^ORCID,Nam Ryoung Hee¹^ORCID,Yu Jeong Eun¹^ORCID,Son Joo Hee¹^ORCID,Lee Sun Min¹^ORCID,Lee Dong Ho¹³^ORCID

Affiliation:

1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

2. Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

3. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

Funder

Seoul National University Bundang Hospital Research Fund

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2021/015/GNL015-01-07.pdf

Reference24 articles.

1. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

2. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy onHelicobacter pylorieradication

3. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

4. Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block

5. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments;Current Gastroenterology Reports;2024-08-15

2. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial;Clinical Drug Investigation;2024-04-13

3. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study;Expert Review of Anti-infective Therapy;2024-03-13

4. Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review;Current Drug Research Reviews;2024-03

5. Antibiotic Resistance of Helicobacter pylori: Mechanisms and Clinical Implications;Journal of Korean Medical Science;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3